Golden, Colorado, Thursday, April 22, 2020 1:00am MDT – Reven, LLC, a biopharmaceutical company that is developing a new drug called Rejuveinix (RJX) for patients suffering cardiovascular and other health conditions, announced today that Michael Volk, Co-Founder, will be stepping into a new role as the firm’s Chief Strategy Officer. At the same time, Volk will be relinquishing his title as Chief Financial Officer.
In this new position, Volk will take on the tasks of developing, focusing, and executing the overall strategy of Reven as it gears up for the introduction of RJX to the marketplace.
Reven is rapidly increasing public awareness of the uniquely special products the company brings to the pharmaceutical industry. As the Chief Strategy Officer, Volk will be responsible for assisting the Chief Executive Officer with developing, executing, and sustaining Reven’s strategic initiatives that create medium- and long-term growth. Volk will mobilize and manage teams charged with executing corporate strategies and act as a resource across the organization to increase broad cohesion for strategic plans.
“Our goal at Reven is to impact cardiovascular disease the same way antibiotics impacted infectious diseases when they were discovered nearly a century ago. Our recent discovery of the apparent link between Covid-19 and cardiovascular conditions, and the impact RJX is anticipated to have in this area, make our contribution to medicine more urgent than ever,” said Volk.
Prior to co-founding Reven, Volk consulted with and started more than 100 companies. He has twenty- six years of executive management experience, twenty of which have been in healthcare, pharmaceuticals, and biotech. His expertise includes taking companies public, and involvement in complex financial transactions to help companies create a sound capital structure.
As Reven continues to make progress toward its global product introduction, it is important for the company to develop the best commercialization and manufacturing strategies possible. “On behalf of the executive team at Reven, I am pleased to announce the transition of Michael Volk into this new capacity. At this crticial time in the company’s growth, and the challenging times in which the medical community finds itself, we are focused on charting the right path for RJX. Michael brings the necessary and valuable expertise to his new role. I am extremely pleased to welcome Michael to the position of Chief Strategy Officer,” said Peter Lange, Founder and CEO.
About Cardiovascular Disease
Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular disease includes coronary artery diseases such as angina and myocardial infarction. Other CVDs include stroke, heart failure, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease and more. Cardiovascular diseases are the leading cause of death globally, of which coronary artery disease and stroke account for 80% of CVD deaths in males and 75% of CVD deaths in females. In the United States, 11% of people between 20 and 40 have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD.
About Reven, LLC
Reven, LLC is a Golden, Colorado based biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of cardiovascular disease. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, RJX, targets Critical Limb Ischemia patients facing amputation as well as a larger patient population suffering PAD and other vascular related medical conditions.
This announcement may contain forward-looking statements. These statements are based on Reven management’s current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those indicated or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to, risks associated with our ability to continue to operate as a going concern; our ability to raise sufficient additional funds to continue operations and to conduct clinical trials of RJX in the United States and elsewhere; our ability to enlist clinical trial sites and enroll patients; the risk that the FDA stops RJX early as a result of the occurrence of certain safety events or does not approve an expansion of RJX; obtaining and maintaining regulatory approvals required to market and sell our products; the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to assumptions regarding the size of the available market; the benefits of our products; product pricing; timing of product launches; future financial results; and other factors.
Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.
Contact: Vincent Vanderbent
Director of Corporate Communications
600 Corporate Circle,
Golden, CO 80401, USA